This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/resource/domain/vavai/projekt/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61388971%3A_____%2F14%3A00441077%21RIV15-GA0-61388971/
n4http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61388971%3A_____%2F14%3A00441077%21RIV15-GA0-61388971
rdf:type
n4:Vysledek skos:Concept
dcterms:description
IL-2 and IL-15 are structurally relative cytokines that share two receptor subunits, CD132 (-y, chain) and CD122 (beta chain). However, the expression pattern and physiological role of IL-2 and IL-15 private receptor a chains CD25 and IL-15Ra, respectively, are strikingly different. CD25, together with CD122 and CD132, forms a trimeric high affinity IL-2 receptor that is expressed and functions on cells acquiring an IL-2 signal. Conversely, IL-15Ra is expressed and binds IL-15 with high affinity per se already in the endoplasmic reticulum of the IL-15 producing cells and it presents IL-15 to cells expressing CD122/CD132 dimeric receptor in trans. Thus, while IL-2 is secreted almost exclusively by activated T cells and acts as a free molecule, IL-15 is expressed mostly by myeloid cells and works as a cell surface-associated cytokine. Interestingly, the in vivo biological activity of IL-2 can be dramatically increased through complexing with certain anti-IL-2 itiAbs; such IL-2/anti-IL-2 mAbs immunocomplexes selectively stimulate the proliferation of a distinct population of immune cells, depending on the clone of the anti-IL-2 mAb used. IL-2/S4B6 mAb immunocomplexes are highly stimulatory for CD122high populations (memory CD8* T and NK cells) and intermediately also for CD25(high) populations (Treg and activated T cells), while IL-2/JES6-1 mAb immunocomplexes enormously expand only 5high cells. Although IL-2 immunocomplexes are much more potent than IL-2 in vivo, they show comparable to slightly lower activity in vitro. The in vivo biological activity of IL-15 can be dramatically increased through complexing with recombinant IL-15Ra-Fc chimera; however, IL-15/IL-15Ra-Fc complexes are significantly more potent than IL-15 both in vivo and in vitro. In this review we summarize and discuss the features and biological relevance of IL-2/anti-IL-2 mAbs and IL-15/1L-15Ra-Fc complexes, and try to foreshadow their potential in immunological research and immunotherapy. IL-2 and IL-15 are structurally relative cytokines that share two receptor subunits, CD132 (-y, chain) and CD122 (beta chain). However, the expression pattern and physiological role of IL-2 and IL-15 private receptor a chains CD25 and IL-15Ra, respectively, are strikingly different. CD25, together with CD122 and CD132, forms a trimeric high affinity IL-2 receptor that is expressed and functions on cells acquiring an IL-2 signal. Conversely, IL-15Ra is expressed and binds IL-15 with high affinity per se already in the endoplasmic reticulum of the IL-15 producing cells and it presents IL-15 to cells expressing CD122/CD132 dimeric receptor in trans. Thus, while IL-2 is secreted almost exclusively by activated T cells and acts as a free molecule, IL-15 is expressed mostly by myeloid cells and works as a cell surface-associated cytokine. Interestingly, the in vivo biological activity of IL-2 can be dramatically increased through complexing with certain anti-IL-2 itiAbs; such IL-2/anti-IL-2 mAbs immunocomplexes selectively stimulate the proliferation of a distinct population of immune cells, depending on the clone of the anti-IL-2 mAb used. IL-2/S4B6 mAb immunocomplexes are highly stimulatory for CD122high populations (memory CD8* T and NK cells) and intermediately also for CD25(high) populations (Treg and activated T cells), while IL-2/JES6-1 mAb immunocomplexes enormously expand only 5high cells. Although IL-2 immunocomplexes are much more potent than IL-2 in vivo, they show comparable to slightly lower activity in vitro. The in vivo biological activity of IL-15 can be dramatically increased through complexing with recombinant IL-15Ra-Fc chimera; however, IL-15/IL-15Ra-Fc complexes are significantly more potent than IL-15 both in vivo and in vitro. In this review we summarize and discuss the features and biological relevance of IL-2/anti-IL-2 mAbs and IL-15/1L-15Ra-Fc complexes, and try to foreshadow their potential in immunological research and immunotherapy.
dcterms:title
Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera
skos:prefLabel
Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera
skos:notation
RIV/61388971:_____/14:00441077!RIV15-GA0-61388971
n3:aktivita
n12:P n12:I
n3:aktivity
I, P(ED1.1.00/02.0109), P(GA13-12885S), P(GAP301/11/0325)
n3:cisloPeriodika
1
n3:dodaniDat
n10:2015
n3:domaciTvurceVysledku
n11:3814556 n11:5287944 n11:4183746
n3:druhVysledku
n9:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
21159
n3:idVysledku
RIV/61388971:_____/14:00441077
n3:jazykVysledku
n7:eng
n3:klicovaSlova
IL-2; IL-15; chimera
n3:klicoveSlovo
n5:chimera n5:IL-15 n5:IL-2
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[F9559E32FAB7]
n3:nazevZdroje
Immunology Letters
n3:obor
n17:EC
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
3
n3:projekt
n6:GAP301%2F11%2F0325 n6:GA13-12885S n6:ED1.1.00%2F02.0109
n3:rokUplatneniVysledku
n10:2014
n3:svazekPeriodika
195
n3:tvurceVysledku
Tomala, Jakub Votavová, Petra Kovář, Marek
n3:wos
000337018400001
s:issn
0165-2478
s:numberOfPages
10